Target intelligence / Profile preview

Mesoderm specific transcript pseudogene 3 (MESTP3)

Target
MESTP3
Molecular classification
Other, Pseudogene
01

Overview

Mesoderm specific transcript pseudogene 3 (MESTP3) is a member of the broad class of pseudogenes in the human genome. Pseudogenes are genomic DNA sequences similar to normal genes but are typically nonfunctional; they arise due to duplication or retrotransposition events followed by sequence decay[4]. Although some pseudogenes can exert regulatory roles—for instance, by acting as decoys for microRNAs or influencing gene expression—there is no evidence that MESTP3 has any specific biological or disease-related function. It should be distinguished from the functional mesoderm specific transcript gene (MEST), which is an imprinted gene encoding a protein implicated in adipose tissue biology and other functions in mice[3][5]. MESTP3 itself does not encode a receptor, enzyme, or other protein relevant for pharmacological targeting or disease association[1]. Note: If your focus is on drug discovery or functional genomics, MESTP3 is not a valid molecular target and should not be confused with the protein-coding MEST gene. No information exists for therapeutic modulation, safety issues, or clinical relevance for MESTP3[1][5].

Other names
mesoderm specific transcript homolog pseudogene 3MESTP3
02

Mechanism of action

None defined. As MESTP3 is a pseudogene and not known to encode a functional protein, there is no mechanism of action relevant to this molecule[1]

03

Biological functions

None established for MESTP3. Pseudogenes in general may have regulatory roles—acting as competitive endogenous RNAs (ceRNAs) or influencing gene expression—but there is no evidence directly describing biological function for MESTP3 itself[1][2].
04

Disease associations

None defined. While other pseudogenes have been linked to disease mechanisms such as cancer, MESTP3 has not been implicated in any disease process in available databases or literature[1][2].
05

Safety considerations

None. There are no safety or therapeutic concerns related to targeting MESTP3, as it is not a functional molecule and not considered a drug target[1].
06

Interacting drugs

None. There are no reported drugs that interact with MESTP3[1].
07

Biomarkers

None. No evidence indicates MESTP3 acts as a biomarker for patient selection or efficacy monitoring[1].

Beyond the preview

Go deeper on Mesoderm specific transcript pseudogene 3 (MESTP3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mesoderm specific transcript pseudogene 3 (MESTP3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call